Fennec Pharmaceuticals Inc (NASDAQ: FENC) has reported a loss for its second fiscal quarter (ending June 30) of $-0.20 versus a loss $-0.21 for the same period a year ago. E.P.S. were $0.10 for the latest four quarters through June 30 versus $-1.00 for the same period a year ago.
Recent Price Action
On 8/13/24, Fennec Pharmaceuticals Inc (NASDAQ: FENC) stock suffered a large decline of -6.4%, closing at $5.85. However, this decline was accompanied by exceptionally low trading volume at 14% of normal. Relative to the market the stock has been extremely weak over the last nine months but has risen 2.1% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, FENC is expected to be Value Creation neutral.
Fennec Pharmaceuticals is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment